Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Polaryx TherapeuticsPLYX +2.73%13 PB Ratio is 42.64 as of Jul. 15, 2026. GuruFocus rates PLYX with a GF Score™ of 13/100. Among 1,228 Biotechnology companies, Polaryx Therapeutics ranks worse than 97.23% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Polaryx Therapeutics PB Ratio Related Terms
Polaryx Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Polaryx Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Polaryx Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaryx Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaryx Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Polaryx Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Polaryx Therapeutics (PLYX) has a PB Ratio of 42.64 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Polaryx Therapeutics and its competitors. According to the industry distribution chart, Polaryx Therapeutics ranks #1194 out of 1228 companies in the Biotechnology industry, placing it in the top 97.2%.
Is Polaryx Therapeutics' PB Ratio too high?
Polaryx Therapeutics' current PB Ratio is 42.64. The Biotechnology industry median PB Ratio is 2.90. Polaryx Therapeutics' value of 42.64 is 1372.9% above this industry median. Based on the distribution chart, Polaryx Therapeutics ranks #1194 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' PB Ratio compare to GUTS and NTHI?
According to the Biotechnology industry distribution chart, Polaryx Therapeutics ranks #1194 out of 1228 companies for PB Ratio. This places Polaryx Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.90. Polaryx Therapeutics' value of 42.64 is 1372.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polaryx Therapeutics's current PB Ratio of 42.64 is 1372.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Polaryx Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polaryx Therapeutics's current PB Ratio is 42.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current PB Ratio of 42.64. The current PB Ratio is 42.64 and 1372.9% above the Biotechnology industry median of 2.90. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current PB Ratio is 42.64 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score
Get the complete analysis for PLYX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYX has been successfully added to your 
